Recombinant Anti-Met (c-Met) (phospho Y1234 + Y1235) antibody [MetY12341235-6F11] (ab278552)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [MetY12341235-6F11] to Met (c-Met) (phospho Y1234 + Y1235)
- Suitable for: Flow Cyt
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Met (c-Met) (phospho Y1234 + Y1235) antibody [MetY12341235-6F11]
See all Met (c-Met) primary antibodies -
Description
Rabbit monoclonal [MetY12341235-6F11] to Met (c-Met) (phospho Y1234 + Y1235) -
Host species
Rabbit -
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide within Human Met (c-Met) (phospho Y1234 + Y1235). The exact immunogen sequence used to generate this antibody is proprietary information. If additional detail on the immunogen is needed to determine the suitability of the antibody for your needs, please contact our Scientific Support team to discuss your requirements.
Database link: P08581 -
Positive control
- Flow cyt: Ramos and NIH/3T3 cells (both treated with pervanadate); Ramos (treated with FBS + pervanadate)
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.02% Sodium azide
Constituents: 49.88% PBS, 50% Glycerol (glycerin, glycerine), 0.1% BSA -
Concentration information loading...
-
Purity
Protein A/G purified -
Clonality
Monoclonal -
Clone number
MetY12341235-6F11 -
Isotype
IgG -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab278552 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
Use a concentration of 0.001 - 1 µg/ml.
|
Notes |
---|
Flow Cyt
Use a concentration of 0.001 - 1 µg/ml. |
Target
-
Function
Receptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival. -
Involvement in disease
Note=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
Note=Defects in MET may be associated with gastric cancer.
Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 3 IPT/TIG domains.
Contains 1 protein kinase domain.
Contains 1 Sema domain. -
Domain
The kinase domain is involved in SPSB1 binding. -
Post-translational
modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 4233 Human
- Entrez Gene: 17295 Mouse
- Omim: 164860 Human
- SwissProt: P08581 Human
- SwissProt: P16056 Mouse
- Unigene: 132966 Human
- Unigene: 86844 Mouse
-
Alternative names
- AUTS9 antibody
- c met antibody
- D249 antibody
see all
Images
-
Flow cytometric analysis of Ramos cells secondary antibody only negative control (blue) or untreated (red) or treated with pervanadate (green) using 0.005 ug/mL ab278552.
-
Flow cytometric analysis of Ramos cells secondary antibody only negative control (blue) untreated (red) treated with FBS + pervanadate (green) treated plus blocked by non-phospho peptide (violet) or treated plus blocked by phospho-peptide (brown) using 0.01 ug/mL ab278552.
-
Flow cytometric analysis of Ramos cells secondary only negative control (blue) or untreated (red) or treated with FBS + pervanadate (green) using ab278552 at 0.01ug/mL.
-
Flow cytometric analysis of NIH3T3 cells secondary antibody only negative control (blue) or 0.1 µg/mL of isotype control (orange) or treated with imatinib (red) or with pervanadate (green) using ab278552 at 0.1 µg/mL.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab278552 has not yet been referenced specifically in any publications.